Morningstar's Xenetic Biosciences Inc Stock Analysis
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Xenetic Biosciences Inc's Company Profile
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer.
Framingham, MA, 01701